06-DEC-2025 6:10

Lung-MAP ACCRUAL REPORT

  O
P
E
N		 ACCR
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
LUNGMAP Screening Protocol Registrations
Total     3833 296 185 98 29 8 02/06/2019 467 187
Screened at PD     1375 135 105 60 19 5      
Pre-Screened prior to PD     2444 147 71 34 8 2      
Treatment-naive     14 14 9 4 2 1      
ctDNA Specimen Submission     315 0 0 0 0 0      
Re-analysis Requests     519 24 14 7 1 0      
 
Sub-Study Assignments
LUNGMAP Sub-Study Assignments     2039 286 139 73 27 10      
Screened at PD     1145 154 99 57 21 9      
Pre-Screened prior to PD     825 115 31 12 3 0      
Treatment-naive     13 13 8 3 2 0      
After PD on a Lung_MAP Sub-Study     56 4 1 1 1 1      
 
Sub-Study Assignments (open studies only)
S1800E     256 256 123 67 24 10      
S1900G     33 6 3 1 1 0      
S1900J     14 6 2 1 0 0      
S1900K     26 18 11 4 2 0      
 
Sub-Study Registrations
LUNGMAP Sub-Study Registrations     556 63 50 25 10 2      
Initial sub-study registrations     544 63 50 25 10 2      
Subsequent sub-study registrations     12 0 0 0 0 0      
 
Patients Registered to a Sub-Study (open studies only)
S1800E: Non-Match: Docetaxel + Ramu +/- Cemiplimab   378 40 40 38 19 7 2 05/22/2025 326 103
Docetaxel plus Ramucirumab Y   21 21 20 9 3 1      
Cemiplimab plus Docetaxel and Ramucirumab Y   19 19 18 10 4 1      
S1900G: EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu   66 23 7 3 2 1 0 05/05/2023 295 106
Capmatinib + Osimertinib + Ramucirumab Y   13 6 3 2 1 0      
Capmatinib + Osimertinib Y   10 1 0 0 0 0      
S1900J: MET Amplification: Amivantamab Hyaluronidase   88 3 2 1 1 0 0 11/19/2024 236 77
Amivantamab Hyaluronidase Y   3 2 1 1 0 0      
S1900K: MET Exon 14: Tepotinib +/- Ramucirumab   56 16 14 8 3 2 0 08/08/2024 275 91
Tepotinib + Ramucirumab Y   10 9 4 2 1 0      
Tepotinib Y   6 5 4 1 1 0